Shares of Bio Blast Pharma Ltd (NASDAQ: ORPN), engaged in the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases, recorded over 16.0% gain during each of the past two consecutive trading sessions with significant number of shares exchanging hands. ORPN was among the top performers in the U.S. healthcare sector after gaining 15.9% and closed at $6.90 Friday, while recording significant trading volumes of 165,947 shares. Recently, ORPN announced that it has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for Cabaletta for the treatment of Spinocerebellar Ataxia Type 3. During the past 5-trading sessions, ORPN gained 45.9% with daily average trading volumes of 79,807 shares, while the stock accumulated 25.5% gain during the past one month with daily average trading volumes of 26,586 shares.
Company Description:
Bio Blast Pharma Ltd. (NASDAQ: ORPN) is a clinical stage biopharmaceutical company. The company identifies licenses, acquires, develops and distributes drugs for rare and ultra-rare genetic and metabolic diseases. Bio Blast Pharmaceutical offers its products to the heathcare and medical industries.
1-Year Stock Chart:
Source: Bloomberg
